Carregant...
Therapeutic activity of agonistic, human anti-CD40 monoclonal Abs requires selective FcγR-engagement
While engagement of the inhibitory Fcγ-Receptor (FcγR) IIB is an absolute requirement for in vivo antitumor activity of agonistic mouse anti-CD40 monoclonal antibodies (mAbs), a similar requirement for human mAbs has been disputed. By using a mouse model humanized for its FcγRs and CD40, we revealed...
Guardat en:
| Publicat a: | Cancer Cell |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2016
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4975533/ https://ncbi.nlm.nih.gov/pubmed/27265505 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ccell.2016.05.001 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|